1e
19
1
49
2
2
18
1b
1d
18
35
9f
1d
2 29
1d
25
Victoria P. Werth, M.D.
78
9f
Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center
7
62
Department: Dermatology
4
1
b
1d
46
Contact information
45
4
3
3
3
2
4
b
1f
45
Division of Dermatology
28 Veterans Administration Hospital
42 University and Woodland Avenues
Philadelphia, PA 19104
26
28 Veterans Administration Hospital
42 University and Woodland Avenues
Philadelphia, PA 19104
2e
Office: 215-823-4208
32 Fax: 215-823-5171
24
f
32 Fax: 215-823-5171
24
13
Education:
21 9 M.S. 1f (Physical Chemistry) c
2c Catholic University, 1976.
21 9 B.A. 16 (Chemistry) c
2c Catholic University, 1976.
21 9 M.D. 15 (Medicine) c
31 Johns Hopkins University, 1980.
c
3
27
21 9 M.S. 1f (Physical Chemistry) c
2c Catholic University, 1976.
21 9 B.A. 16 (Chemistry) c
2c Catholic University, 1976.
21 9 M.D. 15 (Medicine) c
31 Johns Hopkins University, 1980.
c
Links
5d Scleroderma Foundation
61 Philadelphia Dermatology Society
64 Medical Dermatology Society
6d The Myositis Association
69 Lupus Research Institute
75 International Pemphigus and Pemphigoid Foundation
6b Pennsylvania Academy of Dermatology
37 Lupus Foundation of America
c
5
21
5d Scleroderma Foundation
61 Philadelphia Dermatology Society
64 Medical Dermatology Society
6d The Myositis Association
69 Lupus Research Institute
75 International Pemphigus and Pemphigoid Foundation
6b Pennsylvania Academy of Dermatology
37 Lupus Foundation of America
c
1f
Post-Graduate Training
24 59 Intern in Medicine, Northwestern Memorial Hospital, Chicago, 1980-1981.
24 64 Resident in Internal Medicine, Northwestern Memorial Hospital, Chicago, 1981-1983.
24 4a Resident in Dermatology, New York University, 1983-1986.
24 50 Chief Resident in Dermatology, New York University, 1985-1986.
24 51 Research Fellow in Dermatology, New York University, 1986-1988.
24 50 Dermatology Foundation Fellow, New York University, 1987-1989.
c
3
25
24 59 Intern in Medicine, Northwestern Memorial Hospital, Chicago, 1980-1981.
24 64 Resident in Internal Medicine, Northwestern Memorial Hospital, Chicago, 1981-1983.
24 4a Resident in Dermatology, New York University, 1983-1986.
24 50 Chief Resident in Dermatology, New York University, 1985-1986.
24 51 Research Fellow in Dermatology, New York University, 1986-1988.
24 50 Dermatology Foundation Fellow, New York University, 1987-1989.
c
17
Certifications
28 3c American Board of Internal Medicine, 1983.
28 36 American Board of Dermatology, 1986.
28 51 American Boards of Immunodermatology and Immunopathology, 1989.
c
3
8a
Permanent link28 3c American Board of Internal Medicine, 1983.
28 36 American Board of Dermatology, 1986.
28 51 American Boards of Immunodermatology and Immunopathology, 1989.
c
2 29
21
1e
1d
24
5e
1d Tumor necrosis factor
17 Cutaneous lupus
1a Glycosaminoglycans
4b Clinical and translational research in cutaneous autoimmune diseases
65
25 Cutaneous Lupus Erythematosus
17 Dermatomyositis
19 Pemphigus vulgaris
1a 29
27
Description of Research Expertise
1d Photobiology1d Tumor necrosis factor
17 Cutaneous lupus
1a Glycosaminoglycans
4b Clinical and translational research in cutaneous autoimmune diseases
65
Description of Clinical Expertise
28 Autoimmune skin disease25 Cutaneous Lupus Erythematosus
17 Dermatomyositis
19 Pemphigus vulgaris
1a 29
23
129 Cepica TB, Xie L, Faden DF, Stone CJ, Feng R, Werth VP, Chong BF.: Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort study. J Am Acad Dermatol 92(4): 912-914, Apr 2025.
3f6 Zanframundo G, Dourado E, Bauer-Ventura I, Faghihi-Kashani S, Yoshida A, Loganathan A, Rivero-Gallegos D, Lim D, Bozán F, Sambataro G, Bae SS, Yamano Y, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Hansen P, Rozza D, Scirè CA, Sakellariou G, Kaneko Y, Triantafyllias K, Castañeda S, Alberti ML, Merino MGG, Fiehn C, Molad Y, Govoni M, Nakashima R, Alpsoy E, Giannini M, Chinoy H, Gallay L, Ebstein E, Campagne J, Saraiva AP, Conticini E, Sebastiani GD, Nuño-Nuño L, Scarpato S, Schiopu E, Parker M, Limonta M; CLASS project participating investigators; Cavagna L, Aggarwal R.: The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project. Ann Rheum Dis 4967(25), Mar 2025.
1b1 Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C.: Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary. Immunotherapy 17(3): 161-173, Feb 2025.
25b Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA.: Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405(10473): 137-146, Jan 2025.
f6 Xie L, Faden DF, Stone CJ, Lopes Almeida Gomes L, Feng R, Werth VP.: Subtype and Racial Erythema Variation for Cutaneous Lupus Trials. JAMA Dermatol 161(1): 67-74, Jan 2025.
11c Khosravi-Hafshejani T, Werth VP.: Serum IFNα as a Biomarker for Cutaneous Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application. J Invest Dermatol(25), Jan 2025.
f8 Hile GA, Werth VP.: Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics. Arthritis Rheumatol 77(1): 1-11, Jan 2025.
141 Ogawa-Momohara M, Vazquez T, Chin F, Sharma M, Dan J, Sprow G, Werth VP.: Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth, B-Cell-Directed Immunoprofile. J Invest Dermatol 145(1): 190-193, Jan 2025.
12b Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth VP.: Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials. JID Innov 5(2): 100337, Dec 2024.
2c
7
1d
1f
Selected Publications
165 Shen CZ, Carol H, Feng R, Hill A, Lopes Almeida Gomes L, Hejazi EZ, Werth VP, Shaw KS.: Risk of interstitial lung disease in adult patients with dermatomyositis treated with methotrexate: A retrospective analysis of a prospective cohort. J Am Acad Dermatol 92(5): 1098-1100, May 2025.129 Cepica TB, Xie L, Faden DF, Stone CJ, Feng R, Werth VP, Chong BF.: Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort study. J Am Acad Dermatol 92(4): 912-914, Apr 2025.
3f6 Zanframundo G, Dourado E, Bauer-Ventura I, Faghihi-Kashani S, Yoshida A, Loganathan A, Rivero-Gallegos D, Lim D, Bozán F, Sambataro G, Bae SS, Yamano Y, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Hansen P, Rozza D, Scirè CA, Sakellariou G, Kaneko Y, Triantafyllias K, Castañeda S, Alberti ML, Merino MGG, Fiehn C, Molad Y, Govoni M, Nakashima R, Alpsoy E, Giannini M, Chinoy H, Gallay L, Ebstein E, Campagne J, Saraiva AP, Conticini E, Sebastiani GD, Nuño-Nuño L, Scarpato S, Schiopu E, Parker M, Limonta M; CLASS project participating investigators; Cavagna L, Aggarwal R.: The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project. Ann Rheum Dis 4967(25), Mar 2025.
1b1 Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C.: Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary. Immunotherapy 17(3): 161-173, Feb 2025.
25b Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA.: Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405(10473): 137-146, Jan 2025.
f6 Xie L, Faden DF, Stone CJ, Lopes Almeida Gomes L, Feng R, Werth VP.: Subtype and Racial Erythema Variation for Cutaneous Lupus Trials. JAMA Dermatol 161(1): 67-74, Jan 2025.
11c Khosravi-Hafshejani T, Werth VP.: Serum IFNα as a Biomarker for Cutaneous Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application. J Invest Dermatol(25), Jan 2025.
f8 Hile GA, Werth VP.: Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics. Arthritis Rheumatol 77(1): 1-11, Jan 2025.
141 Ogawa-Momohara M, Vazquez T, Chin F, Sharma M, Dan J, Sprow G, Werth VP.: Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth, B-Cell-Directed Immunoprofile. J Invest Dermatol 145(1): 190-193, Jan 2025.
12b Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth VP.: Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials. JID Innov 5(2): 100337, Dec 2024.
2c